⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7647616 | 0.78 | THRB (0.39) | — | |
| SCHEMBL6883366 | 0.67 | — | — | |
| Boric Acid SCHEMBL10950163 | 0.63 | — | — | |
| SCHEMBL7649020 | 0.59 | — | — | |
| SCHEMBL4066708 | 0.59 | — | — | |
| SCHEMBL3212417 | 0.59 | — | — | |
| SCHEMBL17946280 | 0.56 | — | — | |
| SCHEMBL11766376 | 0.54 | — | — | |
| SCHEMBL6324774 | 0.54 | — | — | |
| SCHEMBL537874 | 0.54 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-07-24 | — | — | US | disclosed |
| EP-3922635-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-2928898-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10669290-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2020-06-02 | — | — | US | disclosed |
| CN-111117555-A | Environment-friendly aqueous adhesive and preparation method thereof | 庄明磊 | 2020-05-08 | — | — | CN | disclosed |
| US-20190225628-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-25 | — | — | US | disclosed |
| US-10335425-B2 | Compositions and methods of treating of bacterial infections with β-lactamase inhibitors | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180256614-A1 | COMPOSITIONS AND METHODS OF TREATING OF BACTERIAL INFECTIONS WITH BETA-LACTAMASE INHIBITORS | CASE WESTERN UNIVERSITY | 2018-09-13 | — | — | US | disclosed |
| US-20180194783-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2018-07-12 | — | — | US | disclosed |
| US-9949995-B2 | Compositions and methods of treating of bacterial infections with β-lactamase inhibitors | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-04-24 | — | — | US | disclosed |
| US-8557980-B2 | Methods for forming protected organoboronic acids | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-10-15 | — | — | US | disclosed |
| WO-2011103435-A2 | METHODS FOR FORMING PROTECTED ORGANOBORONIC ACIDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201806-A1 | Methods for Forming Protected Organoboronic Acids | NATIONAL SCIENCE FOUNDATION | 2011-08-18 | — | — | US | disclosed |
| US-7122627-B2 | Lactam inhibitors of Hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| US-20040171556-A1 | Methods for inhibiting proteasome | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-02 | — | — | US | disclosed |
| US-20030008828-A1 | Diagnostic kits; for therapy of viral infection; as assat standard or reagent | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-09 | — | — | US | disclosed |
| EP-1206449-A1 | LACTAM INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001007407-A1 | LACTAM INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |